NCT07708181尚未招募2 期
A Phase 2, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 200
- 主要终点
- Numbers of acute gout flares
研究概览
简要总结
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be 18 Years to 75 Years, both male and female.
- •BMI ≤40 kg/m
- •Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of gouty arthritis.
- •≥4 acute gout flares within 1 year prior to screening
排除标准
- •Gout caused by radiotherapy/chemotherapy, organ transplantation, tumors, etc.
- •Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
- •Presence of severe renal function impairment.
- •Intolerance of subcutaneous injection.
- •Known presence or suspicion of active or recurrent bacterial, fungal, or viral infection at the time of enrollment.
- •Live vaccinations within 8 weeks prior to the start of the study.
- •Use of forbidden therapy.
研究组 & 干预措施
SSGJ-613 100 mg Q4W
Experimental
干预措施: SSGJ-613 100 mg Q4W (Drug)
SSGJ-613 100 mg Q12W
Experimental
干预措施: SSGJ-613 100 mg Q12W (Drug)
SSGJ-613 200 mg Q12W
Experimental
干预措施: SSGJ-613 200 mg Q12W (Drug)
Colchicine 0.5mg
Active Comparator
干预措施: Colchicine 0.5 mg (Drug)
结局指标
主要结局
Numbers of acute gout flares
时间窗: 24 weeks
次要结局
- Numbers of acute gout flares(12 weeks)
- Proportions of subjects with at least 1 acute gout flare(12、24、48weeks)
- Time from randomization to first acute flare.(12、24、48 Weeks)
- Numbers of acute gout flares(12、24 Weeks)
研究者
相似试验
招募中
2 期
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentNCT07340463Nanjing University School of Medicine50
招募中
2 期
IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)diabetic patients pancreatic transplant2025-524834-24-00Centre Hospitalier Universitaire De Nantes15
招募中
1 期
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BNCT07389044IntegerBio80
尚未招募
Unknown
Phase IV Multicentre Study on the Safety and Immunogenicity of Recombinant Hepatitis E Vaccine (E. coli) in Healthy AdultsCTRI/2025/12/099590Urihk Pharmaceutical Private Limited (Subsidiary of Ureka Hong Kong)1,000
招募中
3 期
Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BNCT07606950Fujian Shengdi Pharmaceutical Co., Ltd.540